In response to an increasing demand for wireless systems as an alternative to opioids for managing chronic pain, Stimwave LLC announces plans to expand its commercialization efforts for its neuromodulation devices nationwide.
As part of the expansion, as many as 75 new positions are being added to the company’s sales and clinical teams, with the aim of increasing the market penetration for the Stimwave Wireless Pain Relief systems throughout the United States.
“Our mission is to create innovative, wireless, minimally invasive medical technology to revolutionize neuromodulation as we aim to improve the lives of patients with a cost-effective approach to pain management,” says Laura Tyler Perryman, chairman and CEO of Stimwave, in a media release from the Pompano Beach, Fla-based company. “The Stimwave team is on a journey to innovate and engineer new technology that has never been done before, which is a leap forward for medical science.”
Stimwave products include the Freedom Spinal Cord Stimulation (SCS) System and StimQ Peripheral Nerve Stimulator (PNS) System. Both use Wireless Pain Relief technology as an alternative to opioids for chronic pain management.
[Source(s): Stimwave LLC, Business Wire]
